Basilea Pharmaceutica Ltd., of Basel, Switzerland, said Health Canada approved Zevtera (ceftobiprole medocaril) to treat those 18 and older with hospital-acquired pneumonia, excluding ventilator-associated pneumonia, and with community-acquired pneumonia.